CDIO (Cardio Diagnostics) Return on Sales by Gross Profit

Official company branding of Cardio Diagnostics (CDIO)

Cardio Diagnostics is implementing AI-driven blood screenings for the early detection of myocardial infarctions, ensuring steady demand for consumables. The EpiCheck platform utilizes robotics for the precision analysis of ischemia DNA markers. The gross margin reflects current business efficiency, where a metric value of -2231.90 confirms the pace of recovery. Cardio Diagnostics is also expanding partnerships with clinics, integrating epigenetic tests into primary care.

Return on Gross Profit: Cardio Diagnostics Holdings, Inc. (CDIO) for 04/28/2023 - 11/19/2026

Financial and market metric breakdowns for Cardio Diagnostics (CDIO)

Fundamental valuation:Cardio Diagnostics
Brand item of Cardio Diagnostics Holdings, Inc.

Analyzing the resilience of Cardio Diagnostics (CDIO) to market downturns requires an assessment of its core operational efficiency. Scaling B2B subscriptions for AI-driven genetic analysis platforms must translate into lower unit costs alongside revenue growth. The gross profit margin trend reflects the portion of funds remaining after deducting the cost of services, confirming the company's operational reliability and its ability to service its obligations.